全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2018 

Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer

Full-Text   Cite this paper   Add to My Lib

Abstract:

Colorectal cancer (CRC) is the third common cause of malignancy in the world. The incidence and death rate from this cancer has a trend increasingly, especially in developing countries (1). Chemotherapy and radiation therapy (RT) are considered as appropriated pre-operative and post-operative treatments for locally advanced rectal cancer (LARC), stage II (T3–4N0M0) and III (T1–4N1–2M0). Intravenous administration of 5-fluorouracil (5-FU)-based regimen or oral administration of fluoropyrimidine as capecitabine is commonly used in concurrent time with RT and adjuvant treatment. In 2012, a landmark study from Germany reported that capecitabine could be substituted for 5-FU in pre-operative or post-operative setting for rectal cancer because of its non-inferiority of efficacy and less hemato-toxicity than 5-FU (2). Therefore, capecitabine is proved to be used as an adjuvant setting in NCCN guideline for rectal cancer (3)

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133